Elsevier

The Lancet

Volume 354, Issue 9187, 16 October 1999, Pages 1378-1381
The Lancet

Viewpoint
Shifts in mortality curves: saving or extending lives?

https://doi.org/10.1016/S0140-6736(98)11472-1Get rights and content

First page preview

First page preview
Click to open first page preview

References (22)

  • AR Feinstein

    Tempest in a P-pot?

    Hypertension

    (1985)
  • Cited by (43)

    • Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer

      2014, Journal of Clinical Epidemiology
      Citation Excerpt :

      The potential limitations of these measures in the context of trials of adjuvant therapies for early-stage cancer are described. Difference-in-mean survival is arguably the preferable way of summarizing the absolute treatment effect for time-to-event data [9]. It represents a valid summary of the difference between survival curves, and it is not affected by evolving selection bias.

    • Troponin leak in heart failure: Moving forward to arrest cardiomyocyte attrition and promote myocardial regeneration

      2013, International Journal of Cardiology
      Citation Excerpt :

      This scenario is also consistent with the evidence that therapies aimed at inotropic stimulation of the myocardium with their attendant hastened cardiomyocyte attritions worsen prognosis [10–12], while therapies which suppress the effects of activated neurohumoral systems improved prognosis [17–20,22–24]. The only problem is that these observations which were made in clinical trial populations cannot be directly demonstrable in individual HF patients in everyday clinical practice [57]. The availability of a simple measurement that can reflect these types of injurious effects manifesting as low-grade cTn leakages, would allow clinicians to tailor HF treatment to the individuals and find the best combination of interventions most effective in suppressing the chronic low-grade toxic injuries.

    • Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods

      2012, Annals of Oncology
      Citation Excerpt :

      Although absolute benefits are usually measured at one point, an alternative and perhaps superior measure of the absolute treatment effect can be calculated that uses all of the data. Tan and Murphy [11] proposed a statistic called the ‘average duration of life gained’ (ADLG) as a measure to summarize differences in treatment effect. When reported as life-years gained, ADLG is equal to the area between the curves when survival is plotted on a scale from zero to one and the follow-up is measured in years.

    • How should the efficacy of novel treatments be assessed in survival trials?

      2007, International Journal of Cardiology
      Citation Excerpt :

      Thus the benefit of a novel treatment can be seen in terms of extra years of life rather than as a reduction of risk or the chance of being the one patient to benefit using the NNT concept. The advantages of using the extra life gained have been discussed [3]. The sample mean survival time is asymptotically normally distributed [4,5].

    View all citing articles on Scopus
    View full text